Patents by Inventor Gilles Labesse

Gilles Labesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azaindole derivatives and their use as ERK kinase inhibitors
    Patent number: 11708364
    Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: July 25, 2023
    Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
    Inventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
  • N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS
    Publication number: 20230036867
    Abstract: The present invention relates to N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenylsulfonamide compounds which are useful as inhibitors of protein kinases, more specifically BRAF or mutant forms thereof, to pharmaceutical composition comprising such compounds, and to uses of such compounds in the treatment or prevention of diseases associated with deregulated protein kinase activity, such as cancer.
    Type: Application
    Filed: December 5, 2020
    Publication date: February 2, 2023
    Inventors: Gilles LABESSE, Melanie SCHNEIDER, Muriel GELIN, Jean-François Alexandre GUICHOU, Martin COHEN-GONSAUD, William BOURGUET, Patrick BALAGUER
  • AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS
    Publication number: 20210221809
    Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Applicants: AGV Discovery ENSCM, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite De Montpellier
    Inventors: Jean-François GUICHOU, Cédric BORIES, Clément GEOFFROY, Charline DUQUENNE, Muriel GELIN, Gilles LABESSE, Yannick BESSIN, Loic MATHIEU
  • Zaindole derivatives and their use as ERK kinase inhibitors
    Patent number: 10995089
    Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 4, 2021
    Assignees: AGV DISCOVERY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER
    Inventors: Jean-François Guichou, Cédric Bories, Clément Geoffroy, Charline Duquenne, Muriel Gelin, Gilles Labesse, Yannick Bessin, Loic Mathieu
  • ZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS
    Publication number: 20200283432
    Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 10, 2020
    Applicants: AGV Discovery ENSCM, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier
    Inventors: Jean-François GUICHOU, Cédric BORIES, Clément GEOFFROY, Charline DUQUENNE, Muriel GELIN, Gilles LABESSE, Yannick BESSIN, Loic MATHIEU
  • NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF
    Publication number: 20190040004
    Abstract: Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.
    Type: Application
    Filed: October 9, 2018
    Publication date: February 7, 2019
    Inventors: Denis SERENO, Gilles LABESSE, Jean-Francois Alexandre GUICHOU, Corinne LOEUILLET, Deborah Isabelle GARCIA, Stephane DELBECQ
  • N-hydroxybenzamides as HDAC inhibitors for the treatment of parasitic diseases
    Patent number: 10106493
    Abstract: Compounds of formula wherein n is 0, 1 or 2; X is and Ar is a benzyl substituted at the meta position by a C1 to C8 alkoxy group, or a pharmaceutically acceptable salt thereof, for treating, preventing or inhibiting a parasitic disease, such as toxoplasmosis, in a subject are provided. Methods for preparing the compounds are also presented.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: October 23, 2018
    Assignees: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.), UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Denis Sereno, Gilles Labesse, Jean-Francois Alexandre Guichou, Corinne Loeuillet, Deborah Isabelle Garcia, Stephane Delbecq
  • Phosphodeoxyribosyl transferase mutant enzymes and uses thereof
    Patent number: 9523084
    Abstract: The present invention relates to enzyme mutants obtained from the nucleoside deoxyribosyltransferase (NDT) of Lactobacilli bacteria. These mutants are surprisingly able to exchange deoxyribose mono-, bi- and triphosphate between various nucleobases. In vitro syntheses have been successfully performed with several nucleobase analogs. These enzyme mutants provide new tools to synthesize, in vitro and/or in vivo, dNTPs or analogs thereof.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 20, 2016
    Assignee: Centre National De La Recherche Scientifique (CNRS)
    Inventors: Pierre-Alexandre Kaminski, Gilles Labesse
  • NEW COMPOUNDS FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES AND METHOD OF PRODUCTION OF THEREOF
    Publication number: 20160168084
    Abstract: Disclosed are new compounds for treating, preventing or inhibiting a parasitic disease, preferably toxoplasmosis in a subject, the method for preparing thereof.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 16, 2016
    Inventors: Denis SERENO, Gilles LABESSE, Jean-Francois Alexandre GUICHOU, Corinne LOEUILLET, Deborah Isabelle GARCIA, Stephane DELBECQ
  • Phosphodeoxyribosyl Transferase Mutant Enzymes and Uses Thereof
    Publication number: 20150267181
    Abstract: The present invention relates to enzyme mutants obtained from the nucleoside deoxyribosyltransferase (NDT) of Lactobacilli bacteria. These mutants are surprisingly able to exchange deoxyribose mono-, bi- and triphosphate between various nucleobases. In vitro syntheses have been successfully performed with several nucleobase analogs. These enzyme mutants provide new tools to synthesize, in vitro and/or in vivo, dNTPs or analogs thereof.
    Type: Application
    Filed: November 8, 2013
    Publication date: September 24, 2015
    Inventors: Pierre-Alexandre Kaminski, Gilles Labesse
  • Antibacterial compounds
    Patent number: 8927520
    Abstract: The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim 1. The compounds are useful in the prevention and/or treatment of bacterial infections.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 6, 2015
    Assignees: Institut Pasteur, Institut Curie
    Inventors: Sylvie Pochet, Gilles Labesse, Muriel Gelin, Liliane Assairi, Olivier Dussurget, Guillaume Poncet-Montange
  • NOVEL ANTIBACTERIAL COMPOUNDS
    Publication number: 20130331351
    Abstract: The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim 1. The compounds are useful in the prevention and/or treatment of bacterial infections.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 12, 2013
    Applicants: Institut Pasteur, INSTITUT CURIE, Centre National De la Recherche Scientifique
    Inventors: Sylvie Pochet, Gilles Labesse, Muriel Gelin, Liliane Assairi, Olivier Dussurget, Guillaume Poncet-Montange
  • USE OF THE PROTIEN MABA (FABG1) OF MYCOBACTERIUM TUBERCULOSIS FOR DESIGNING AND SCREENING ANTIBIOTICS
    Publication number: 20100240084
    Abstract: The protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The uses of proteins MabA, or recombinant proteins derived from protein MabA by mutation of at lease one amino acid, proteins and to the crystalloghraphis co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of these proteins, and advantageously, ligands inhibiting the enzymatic activity of these proteins.
    Type: Application
    Filed: April 14, 2009
    Publication date: September 23, 2010
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER 1
    Inventors: Annaik QUEMARD, Gilles Labesse, Mamadou Daffe, Hedia Marrakchi, Dominique Douguet, Martin Cohen-Gonsaud, Stephanie Ducasse
  • COMPLEXES OF NADP WITH THE PROTEIN MABA OF MYCOBACTERIUM TUBERCULOSIS OR WITH MUTANTS THEREOF, AND THEIR USES FOR DESIGNING AND SCREENING ANTIBIOTICS
    Publication number: 20100113291
    Abstract: The main subject of the present invention is the use of complexes of NADP with the protein MabA, or with a derived protein, and more particularly the crystallographic coordinates of these proteins in the frame of said complexes, within the framework of the implementation of methods for designing and screening ligands of these proteins, and advantageously ligands inhibiting the enzymatic activity of these proteins, namely antibiotics capable of being used within the framework of the treatment of mycobacteriosis.
    Type: Application
    Filed: March 20, 2007
    Publication date: May 6, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Labesse, Annaïk Quemard, Martin Gonsaud, Stéphanie Ducasse-Cabanot, Mamadou Daffe
  • Aryl, Pyrimidyl Compounds, Pharmaceutical Compositions Comprising them, Their Use as Antimicrobial Agents
    Publication number: 20080096907
    Abstract: Substituted aryl pyrimidyl compounds responding to formula (I) and their use for the preparation of a medicament for the prevention and/or treatment of a pathology caused by a mycobacteria.
    Type: Application
    Filed: November 4, 2005
    Publication date: April 24, 2008
    Applicants: INSTITUT PASTEUR, INSTITUT NAT. DE LA SANTE DE LA RECHERCHE MED., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Helene Munier-Lehmann, Dominique Douguet, Gilles Labesse, Sylvie Pochet
  • Use of the protein maba (fabg1) of mycobacterium tuberculosis for designing and screening antibiotics
    Publication number: 20060035294
    Abstract: The invention especially relates to the protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The invention also relates to the uses of said proteins and to the crystallographic co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of said proteins, and advantageously, ligands inhibiting the enzymatic activity of said proteins.
    Type: Application
    Filed: March 28, 2003
    Publication date: February 16, 2006
    Inventors: Annaik Quemard, Gilles Labesse, Mamadou Daffe, Hedia Marrakchi, Dominique Douguet, Martin Cohen-Gonsaud, Stephanie Ducasse